U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07468396) titled 'A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer' on March 03.
Brief Summary: A Phase I Clinical Study of GLR2037 in Patients with Advanced Prostate Cancer
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DRUG: GLR2037
GLR2037 administered QD for 28 day cycles.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Gan & Lee Pharmaceuticals.
Disclaimer: Curated by HT Syndication....